



CCM DUOPHARMA BIOTECH BERHAD (524271-W)
(Incorporated in Malaysia)
UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE PERIOD ENDED 30 SEPT 2010

	INDIVIDUAL PERIOD		CUMULATIVE PERIOD	
	CURRENT YEAR QUARTER 9/30/2010 RM'000	PRECEDING YEAR CORRESPONDING QUARTER 9/30/2009 RM'000	CURRENT YEAR TO DATE 9/30/2010 RM'000	PRECEDING YEAR CORRESPONDING PERIOD 9/30/2009 RM'000
Revenue	34,464	32,188	99,242	93,916
Cost of Sales	(18,184)	(17,125)	(55,821)	(47,268)
Gross Profit	16,280	15,063	43,421	46,648
Other operating income	103	215	504	633
Distribution costs	(3,176)	(2,778)	(8,665)	(8,490)
Administration expenses	(2,405)	(2,364)	(6,737)	(7,067)
Other operating expenses	(571)	(857)	(1,689)	(2,088)
Profit from operations	10,231	9,279	26,834	29,636
Finance costs	(10)	(11)	(32)	(31)
Profit before taxation	10,221	9,268	26,802	29,605
Taxation	(2,602)	(2,339)	(6,747)	(7,216)
Profit after tax for the period	7,619	6,929	20,055	22,389
Other comprehensive income for the period, net of tax	-	-	-	-
Total comprehensive income for the period	7,619	6,929	20,055	22,389
Profit attributable to:				
Owners of the parent	7,619	6,929	20,055	22,389
Non-controlling interest	-	-	-	-
	7,619	6,929	20,055	22,389
Total comprehensive income attributable to :				
Owners of the parent	7,619	6,929	20,055	22,389
Non-controlling interest	-	-	-	-
	7,619	6,929	20,055	22,389
Earnings per share (sen)				
Basic (based on weighted average)	5.49	4.99	14.45	16.13
Diluted (based on weighted average)	5.49	4.99	14.45	16.13

(The Condensed Consolidated Statement of Comprehensive Income should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2009 and the accompanying explanatory notes attached to the interim financial statements.)



CCM DUOPHARMA BIOTECH BERHAD (524271-W)

(Incorporated in Malaysia)

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 30 SEPT 2010

	AS AT END OF CURRENT PERIOD 30/9/2010 RM'000	AS AT PRECEDING FINANCIAL YEAR ENDED 31/12/2009 RM'000
ASSETS		
Property, Plant and Equipment	92,213	74,840
Total non-current assets	<u>92,213</u>	<u>74,840</u>
Inventories	33,243	36,353
Trade & Other Receivables	36,428	34,086
Related Company	860	1,023
Current tax assets	-	63
Cash & Cash Equivalents	24,957	26,999
Total current assets	<u>95,488</u>	<u>98,524</u>
Total Assets	<u><u>187,701</u></u>	<u><u>173,364</u></u>
EQUITY		
Share Capital	69,739	69,739
Reserves	80,394	74,577
Treasury Shares	(1,578)	(1,578)
Total Equity	<u>148,555</u>	<u>142,738</u>
LIABILITIES		
Deferred Tax Liability	4,422	4,466
Term Loan	12,499	9,175
Total non-current liabilities	<u>16,921</u>	<u>13,641</u>
Trade & Other Payables	10,949	9,052
Amount due to related company	975	1,016
Provision	444	666
Taxation	1,523	-
Term Loan	8,334	6,251
Total current liabilities	<u>22,225</u>	<u>16,985</u>
Total Liabilities	<u>39,146</u>	<u>30,626</u>
Total Equity & Liabilities	<u><u>187,701</u></u>	<u><u>173,364</u></u>
Net assets per share (RM)	1.07	1.02

(The Condensed Consolidated Statement of Financial Position should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2009 and the accompanying explanatory notes attached to the interim financial statements.)



CCM DUOPHARMA BIOTECH BERHAD (524271-W)
(Incorporated in Malaysia)
UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOW
FOR THE PERIOD ENDED 30 SEPT 2010

	30 Sept 10 RM '000	30 Sept 2009 RM '000
Cash generated from operations:	32,898	22,125
Income taxes paid	(5,207)	(5,841)
Net cash generated from operating activities	27,691	16,284
Net cash used in investing activities	(20,911)	(8,793)
Cash generated from financing activities		
Dividend paid	(14,229)	(9,718)
Drawdown of term loan	5,407	-
Net cash used in financing activities	(8,822)	(9,718)
Net (decrease) / increase in cash and cash equivalents	(2,042)	(2,227)
Cash and cash equivalents as at 1 Jan	26,999	18,424
Cash and cash equivalents as at 30 Sept (I)	24,957	16,197

(I) Cash and cash equivalents comprise:

	<u>RM '000</u>	<u>RM '000</u>
Cash and bank balances	7,440	2,847
Fixed deposits placed with licensed financial institutions	17,517	13,350
	24,957	16,197

(The Condensed Consolidated Statement of Cash Flow should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2009 and the accompanying explanatory notes attached to the interim financial statements.)